Patients with cystic fibrosis who take the drug ivacaftor regularly have less respiratory infections compared to those who do not take the drug, finds a study published in the Annals of the American Thoracic Society.
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor (Kalydeco®) is prescribed to patients whose CF is caused by a "gating" mutation. This group of mutations, which are responsible for about 4 percent of all CF cases, prevents chloride from moving in and out of cells. By restoring the gate's function, ivacaftor has been shown to improve lung function and quality of life.
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor (Kalydeco®) is prescribed to patients whose CF is caused by a "gating" mutation. This group of mutations, which are responsible for about 4 percent of all CF cases, prevents chloride from moving in and out of cells. By restoring the gate's function, ivacaftor has been shown to improve lung function and quality of life.
In "Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens: A Cohort Study Using National Registry Data," researchers in the U.K. report that ivacaftor may also reduce some of the most common lung infections in patients with CF, including P. aeruginosa. If this is true, they say, it may mean that some patients taking ivacaftor can take fewer antibiotics long term and still remain clinically stable.
‘Patients with cystic fibrosis could potentially take fewer antibiotics and remain clinically stable upon regular intake of ivacaftor.’
Using data from a CF registry in the U.K., the authors compared CF patients (age six and older) who took ivacaftor with those CF patients who did not take the drug over a three-year period.
The study found that ivacaftor was associated with a 32 percent reduction in the number of people infected with P. aeruginosa and a 15 percent reduction in Staphylococcus aureus. These reductions resulted from both increased clearance of the infection in those already infected and in reduced acquisition in those not infected.
The authors said that with people starting ivacaftor and other drugs that correct defects in the CF gene from an early age, the possibility of preventing these infections is particularly exciting. "If these drugs are taken before chronic infection starts, the risk of developing infection in the future may be reduced considerably," Dr. Frost said.
Ivacaftor was also associated with reduced Aspergillus spp. infections. The drug did not appear to reduce Burkholderia cepacia complex infections.
Dr. Frost said that the study adds to the increasing evidence of the long-term benefits of ivacaftor. "However," he added, "randomized, controlled trials will be needed to know if it is safe to reduce the overall treatment burden of CF by decreasing antibiotic use in patients taking ivacaftor or other drugs that target defects in the CF gene."
Source: Eurekalert
- << Breakthrough Finding for Low Blood Pressure Condition
- Hot Bath 90 Minutes Before Bedtime promotes quality Sleep >>
Recommended Reading
Cystic Fibrosis
Cystic fibrosis is a genetic disease involving the mucus and sweat glands and the medical world has still to find its cure
Bronchiolitis
Bronchiolitis is an acute lower respiratory infection, which is common among the children under 2 years of age.
Measles
Measles is a viral infection with symptoms of fever,and rashes. Measles is prevented by vaccination and staying away from the infected individuals.
Conjunctivitis
Conjunctivitis or Pink Eye causes redness and soreness of the conjunctiva and is responsible for 1% of all emergency visits to a hospital.
Asbestosis
Asbestosis is a chronic inflammatory lung disease that occurs due to long term exposure to asbestos fibres
